Pacritinib
 | |
| Clinical data | |
|---|---|
| Trade names | Vonjo |
| Other names | SB1518 |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H32N4O3 |
| Molar mass | 472.589 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.[1][2][3][4]
It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.[2]
Medical uses
[edit]Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL.[1][2]
History
[edit]The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.[2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24.[2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group.[2]
The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations.[2][5]
Society and culture
[edit]Names
[edit]Pacritinib is the International nonproprietary name (INN).[6][7]
References
[edit]- 1 2 3 "Vonjo- pacritinib capsule". DailyMed. 7 March 2022. Retrieved 24 March 2022.
- 1 2 3 4 5 6 7 8 "FDA approves drug for adults with rare form of bone marrow disorder". U.S. Food and Drug Administration. 1 March 2022. Archived from the original on 1 March 2022. Retrieved 3 March 2022.
This article incorporates text from this source, which is in the public domain. - ↑ Mascarenhas J (August 2022). "Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia". Expert Review of Hematology. 15 (8): 671–684. doi:10.1080/17474086.2022.2112565. PMID 35983661.
- ↑ Yang DH, Lu Q, Zhu Z, Huang G, Young K (December 2022). "Pacritinib for myelofibrosis in adults with thrombocytopenia". Drugs of Today. 58 (12): 577–589. doi:10.1358/dot.2022.58.12.3474538. PMID 36651066.
- ↑ Lamb YN (May 2022). "Pacritinib: First Approval". Drugs. 82 (7): 831–838. doi:10.1007/s40265-022-01718-y. PMID 35567653.
- ↑ "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4): 386. 2010. hdl:10665/74579.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). 2011. hdl:10665/74683.
External links
[edit]- "Pacritinib". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 21 October 2020.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |